Latest filingAug 28, 2026Most recent Form 4
FLGT
Fulgent Genetics, Inc.
NasdaqHealthcareServices-Medical Laboratories
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$4.24M2 sells
Net open-market-$4.24M4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period4transactions
- F · Tax withholding · dominant2 · 50%
- S · Open-market sells2 · 50%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- Chief executive officer · dominant1 · 20%
- Chief financial officer1 · 20%
- CSO1 · 20%
- PRES1 · 20%
- TRES1 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (4)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeKim PaulCommon Stock · Direct
358,630Aug 26, 2026
Hsieh MingCommon Stock · Direct
890,344Aug 26, 2026
Gao HanlinCommon Stock · Direct
987,790Aug 27, 2026
Xie JianCommon Stock · Direct
362,051Aug 27, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- HM-$58.4k
- XJ-$23.7k
- KP-$23.1k
- GH-$18.7k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
FLGT transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| FLGT | Hsieh Ming | CEO | withholding | 2.94k | -$5.84M | F | — | 08/28 | 08/26 | |
| FLGT | Kim Paul | CFOTRES | withholding | 1.16k | -$2.31M | F | — | 08/28 | 08/26 | |
| FLGT | Xie Jian | PRES | sale | 1.19k | -$2.37M | S | — | 08/28 | 08/27 | |
| FLGT | Gao Hanlin | CSO | sale | 939 | -$1.86M | S | — | 08/28 | 08/27 |
Fulgent Genetics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Fulgent Genetics, Inc.?
Hsieh Ming, Kim Paul, Xie Jian, Gao Hanlin.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Xie Jian reported a sale on Aug 27, 2026 valued at $2.37M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $42,438.10. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.